Medicare Enrolled

Dr. Roueen Rafeyan, M.D.

Addiction Medicine (Psychiatry & Neurology) Physician · Chicago, IL
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
2525 S MICHIGAN AVE, Chicago, IL 60616
3125676691
Registered in NPPES since 2005
NPI: 1003891458 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Rafeyan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rafeyan? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Rafeyan

Dr. Roueen Rafeyan is an addiction medicine physician in Chicago, IL, with 20 years of NPI registration. Based on federal Medicare data, Dr. Rafeyan performed 293 Medicare services in 2023. These records do not provide a deduplicated patient total.

Between the years covered by Open Payments, Dr. Rafeyan received a total of $2,342,549 from 35 pharmaceutical and/or device companies across 3132 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Rafeyan is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years of NPI registration ▲ Top 38% volume in IL $2,342,549 industry payments

Medicare Practice Summary — 2023

Medicare Utilization ↗
293
Medicare services
Top 38% in IL for addiction medicine (psychiatry & neurology) physician
Not available
Unique patients (not deduplicated)
$62
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Psychotherapy and evaluation, 30 minutes
A combined session involving psychotherapy and an evaluation and management visit lasting 30 minutes.
123 $46 $100
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
83 $87 $125
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
62 $64 $100
Office visit, established patient (10-19 min)
An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition.
25 $47 $75
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.

Industry Payment Transparency

Open Payments through 2024 ↗
$2,342,549
Total received (2018-2024)
Avg $334,650/year across 7 years
Top 0% in IL for addiction medicine (psychiatry & neurology) physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
35
Companies
3,132
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →

Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$368,926
2023
$429,489
2022
$349,636
2021
$284,760
2020
$154,462
2019
$367,934
2018
$387,341

Payments by company (2024)

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
$105,322
Alkermes, Inc.
$49,153
Neurocrine Biosciences, Inc.
$46,291
Teva Pharmaceuticals USA, Inc.
$45,887
Otsuka America Pharmaceutical, Inc.
$44,831
Axsome Therapeutics, Inc.
$32,698
Janssen Pharmaceuticals, Inc
$17,238
E.R. Squibb & Sons, L.L.C.
$15,789
ABBVIE INC.
$11,493
Lundbeck LLC
$132
IDORSIA PHARMACEUTICALS US INC
$30
ACADIA Pharmaceuticals Inc
$28
Takeda Pharmaceuticals U.S.A., Inc.
$21
Indivior Inc.
$14
Top 3 companies account for 54.4% of 2024 payments
All-time payments by company (2018-2024) ›
Otsuka America Pharmaceutical, Inc.
$474,374
Alkermes, Inc.
$442,111
ITI, Inc.
$246,811
Teva Pharmaceuticals USA, Inc.
$240,728
Neurocrine Biosciences, Inc.
$202,466
Sunovion Pharmaceuticals Inc.
$170,520
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
$105,322
Janssen Pharmaceuticals, Inc
$96,136
H. Lundbeck A S
$82,186
Neurocrine BioSciences, Inc.
$76,075
Axsome Therapeutics, Inc.
$70,335
ABBVIE INC.
$34,684
Takeda Pharmaceuticals U.S.A., Inc.
$29,229
Otsuka Pharmaceutical Development & Commercialization, Inc.
$15,925
E.R. Squibb & Sons, L.L.C.
$15,789
Allergan Inc.
$13,877
AbbVie Inc.
$9,339
Vanda Pharmaceuticals Inc.
$7,354
Allergan, Inc.
$4,239
Lundbeck LLC
$1,827
USWM, LLC
$1,758
Indivior Inc.
$446
Bausch Health US, LLC
$324
Janssen Scientific Affairs, LLC
$135
IDORSIA PHARMACEUTICALS US INC
$111
Neuronetics, Inc.
$107
Supernus Pharmaceuticals, Inc.
$80
Noven Therapeutics, LLC
$65
JAZZ PHARMACEUTICALS INC.
$53
Shire North American Group Inc
$38
ACADIA Pharmaceuticals Inc
$28
Orexo US, Inc.
$21
US WorldMeds, LLC
$20
Jazz Pharmaceuticals Inc.
$19
Noven Pharmaceuticals, Inc.
$14
Top 3 companies account for 49.7% of all-time payments
Associated products mentioned in payments ›
ABILIFY ASIMTUFII · ABILIFY MAINTENA · ABILIFY MYCITE · APLENZIN · ARISTADA · AUSTEDO · Aristada 441 mg · Austedo XR · Auvelity · BRINTELLIX · CAPLYTA · COBENFY · FANAPT · Fanapt · HETLIOZ · INGREZZA · INVEGA SUSTENNA · INVEGA TRINZA · LATUDA · LYBALVI · Lucemyra · Lucemyra/Lofexidine · NEUROSTAR TMS THERAPY · NUEDEXTA · NUPLAZID · PERSERIS · QELBREE · QUVIVIQ · REXULTI · SECUADO · SPRAVATO · SUBLOCADE · SUBOXONE SUBLINGUAL FILM · SUNOSI · TRINTELLIX · Trintellix · UZEDY · VIIBRYD · VIVITROL · VRAYLAR · VYVANSE · Vivitrol · Vivitrol 380 mg · WELLBUTRIN · ZIMHI · Zubsolv
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Looking for an addiction medicine physician in Chicago?
Compare addiction medicine physicians in the Chicago area by procedure volume, costs, and industry payment transparency.
Browse addiction medicine physicians nearby

Geographic Context

Addiction medicine physicians in nearby ZIP areas
15
County median income
$81,797
Nearest hospital to ZIP centroid (approximate)
INSIGHT HOSPITAL AND MEDICAL CENTER CHICAGO
0.0 mi

Data Sources

Provider Registry NPPES NPPES snapshot; verify current record
Medicare Enrollment PECOS PECOS snapshot
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not included N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Rafeyan is a clinical cardiology specialist, with moderate Medicare volume, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Rafeyan experienced with psychotherapy and evaluation, 30 minutes?
Based on Medicare claims data, Dr. Rafeyan performed 123 psychotherapy and evaluation, 30 minutes services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Rafeyan receive payments from pharmaceutical companies?
Yes. Dr. Rafeyan received a total of $2,342,549 from 35 companies across 3,132 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rafeyan's costs compare to other addiction medicine physicians in Chicago?
Dr. Rafeyan's average Medicare payment per service is $62. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rafeyan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
About this page

This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Industry payment disclosure alone establishes neither wrongdoing nor legality. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →